Drug Topics

APRIL 19, 2024

Representatives from the US Government Accountability Office (GAO) interviewed regulators from 5 states on pharmacy benefit manager laws.

233

233

Pharmacy Times

APRIL 19, 2024

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases

148

148

Drug Topics

APRIL 19, 2024

Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.

220

220

Pharmacy Times

APRIL 19, 2024

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

Chemotherapy 139

Chemotherapy 139

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

APRIL 19, 2024

A Q&A with Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee.

Independent Pharmacies 201

Independent Pharmacies Insurance 201

Pharmacy Times

APRIL 19, 2024

The primary endpoint of the study was clinical remission at week 52 with vedolizumab

FDA 139

FDA 139

Fierce Healthcare

APRIL 19, 2024

UnitedHealth Group subsidiary Optum appears to have laid off a significant percentage of its workforce, Fierce Healthcare has learned, though the full extent of those job cuts remains unclear. | UnitedHealth Group subsidiary Optum appears to have laid off a significant percentage of its workforce, Fierce Healthcare has learned, though the full extent of those job cuts remains unclear.

137

137

Pharmacy Times

APRIL 19, 2024

In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.

131

131

STAT

APRIL 19, 2024

Every so often, the conversations that people in health care have become so pervasive that they dominate the zeitgeist, intersecting with mainstream media and popular culture. Oprah Winfrey’s recent ABC special “Shame, Blame, and the Weight Loss Revolution” is a good example of this. Now streaming on Hulu, the broadcast garnered widespread attention, including coverage from People Magazine and The New York Times.

129

129

Fierce Pharma

APRIL 19, 2024

Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. | Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured an FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations.

FDA 126

FDA 126

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Topics

APRIL 19, 2024

Listening carefully to determine what’s beneath the surface of a patient’s concerns can make a world of difference in providing quality care.

123

123

Fierce Healthcare

APRIL 19, 2024

A Pennsylvania provider group has filed suit against Aetna this week, alleging the insurer conducted multiple breaches of contract. | A Pennsylvania provider group has filed suit against Aetna this week, alleging the insurer conducted multiple breaches of contract.

Insurance 120

Insurance 120

PharmaVoice

APRIL 19, 2024

Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.

119

119

Pharmacy Times

APRIL 19, 2024

With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.

FDA 118

FDA 118

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

APRIL 19, 2024

WASHINGTON — A federal rule aiming to make reimbursement for breakthrough devices easier is slated for early summer, a Centers for Medicare and Medicaid Services official said on Thursday. The agency has faced intense pressure from device makers frustrated with the slow pace of Medicare reimbursement decisions. Medical technology lobby AdvaMed sent CMS a strongly-worded letter  in March asking why it has taken so long to get the breakthrough device program moving.

Insurance 116

Insurance 116

Fierce Healthcare

APRIL 19, 2024

Portable defibrillator company Avive Solutions raised $56.5 million in growth equity financing to build out its staff and commercial developments. | The company, which launched in 2017, has contracts with four cities for its network of AEDs to improve survival rates of sudden cardiac arrest. It has raised tens of millions to expand operations.

116

116

pharmaphorum

APRIL 19, 2024

Roche's Alecenesa has become the first ALK inhibitor to be approved by the FDA for adjuvant use in early-stage, ALK+ NSCLC

FDA 115

FDA 115

Fierce Healthcare

APRIL 19, 2024

Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry.

116

116

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

APRIL 19, 2024

Stay updated on the latest STEM Healthcare news from Reuters Pharma USA 2024, featuring insights from global account lead at STEM, Serena Goodwin on the impact of AI in healthcare.

114

114

Drug Topics

APRIL 19, 2024

This approval is the second biosimilar approval for manufacturer Alvotech.

FDA 112

FDA 112

STAT

APRIL 19, 2024

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

111

111

Drug Topics

APRIL 19, 2024

While prioritizing either cost or margin may be necessary at a site of care, big picture items, such as societal responsibility and long-term health care affordability, should guide financial analyses, said Scott Soefje, PharmD.

112

112

pharmaphorum

APRIL 19, 2024

Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever

111

111

Drug Topics

APRIL 19, 2024

Check out important updates from the FDA for the week of April 15.

FDA 112

FDA 112

STAT

APRIL 19, 2024

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape. However, we do foresee several naps in our future, if only to recover from promenading with the official mascots. We also hope to catch up on our reading and hold another listening party with Mrs.

107

107

Pharmaceutical Commerce

APRIL 19, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Niklas Adamsson, COO, Environtainer, suggests how to improve visibility and risk management for cold chain shipping.

105

105

pharmaphorum

APRIL 19, 2024

Cerevel's first phase 3 trial of Parkinson's drug tavapadon is positive - good news for AbbVie which is trying to buy the biotech for $8.

105

105

Fierce Pharma

APRIL 19, 2024

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. | This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness.

105

105

Pharmaceutical Commerce

APRIL 19, 2024

The latest news for pharma industry insiders.

105

105

The Checkup by Singlecare

APRIL 19, 2024

You have a cramping, burning, or gnawing feeling in your stomach, and you know you’re not hungry or sick. What’s causing this discomfort? If you’ve been going through a difficult period, it could be stress-induced stomach pain —abdominal pain that’s triggered by stress and anxiety. Whether you have an underlying condition that intensifies during periods of excess stress or your pain is caused by a single, stressful event, abdominal distress is no picnic.

Compounding 105

Compounding Immunization 105

pharmaphorum

APRIL 19, 2024

Researchers in the US have developed an artificial intelligence tool that can predict how a patient will respond to cancer treatment

105

105

Fierce Pharma

APRIL 19, 2024

Nearly a year and a half after FibroGen slapped a pair of former employees with a lawsuit alleging trade secrets theft, both the plaintiffs and the defendants are walking away from the case little | Nearly a year and a half after FibroGen slapped a pair of former employees with a lawsuit alleging trade secrets theft, both the plaintiffs and the defendants are walking away from the case little worse for wear.

105

105

European Pharmaceutical Review

APRIL 19, 2024

Conclusions from the meeting of the special European Council (17-18 April 2024) have recognised a need for new European competitiveness deal “anchored in a fully integrated Single Market”. Collaboration was highlighted by the Council as an essential factor to “close growth, productivity and innovation gaps between the Union and its international partners and main competitors… [therefore] policy action must be better put at the service of enhancing Europe’s economic, manufacturing, industrial and

105

105